Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › About Us › Our Staff › staff reporter

staff reporter

Email
[email protected]

Articles Authored by staff reporter

Jul 14, 2020

Singapore's Avatamed Expands Global Collaboration to Europe, Partners With CBmed

Through the public-private consortium of companies and institutions across Asia and Austria, the company aims to advance biomarker-driven cancer research.

Jul 14, 2020

Merus, Caris Life Sciences Partner to ID NRG1 Fusion-Positive Cancer Patients for Clinical Trial

Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.

Jul 14, 2020

MD Anderson, Sanofi Announce Five-Year Precision Oncology Partnership

The alliance will join Sanofi's oncology pipeline with MD Anderson's premier clinical trials infrastructure to identify new biomarkers and streamline patient selection.

Jul 13, 2020

Oncology Venture Acquires Full Ownership of Cancer Drugs 2X-121, 2X-111

Both drugs are being investigated in cancer patients harboring biomarkers detected by the company's drug response predictor platform.

Jul 10, 2020

Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis

The analysis suggested survival and other benefits for breast cancer patients with BRCA1/2 mutations who were aware of their germline risk before diagnosis.

Jul 10, 2020

Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.

Jul 10, 2020

Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men

Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.

Jul 09, 2020

JS InnoPharm Doses First Patient in Phase I Trial of ERK Inhibitor JSI-1187

The study will evaluate the safety, tolerability and clinical activity of JSI-1187 in patients with relapsed, refractory solid tumors containing mutations in the MAPK pathway.

Jul 08, 2020

Eli Lilly, Sermonix Pharma Partner on Phase II Trial of Drug Combo in Metastatic Breast Cancer

The open-label, multi-center trial will start enrolling patients in the third quarter to evaluate the safety of lasofoxifene combined with abemaciclib.

Jul 08, 2020

PARP Inhibitor Lynparza Receives EU Approval for Germline BRCA-Mutated Pancreatic Cancer

The approval will make Merck and AstraZeneca's Lynparza available to patients in the EU who have not progressed after 16 weeks on platinum-based chemotherapy.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.